Revised cell therapy for recurrent brain cancer
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of brain cancer called glioblastoma that has returned or progressed.
- You are between 18 and 70 years old.
- Your tumor tissue has at least 1% of cells with CD44 or CD133 markers (for the second phase of the trial).
- You have at least one measurable tumor that is no larger than 3 cm across.
- You have had prior treatment with radiation, temozolomide, or bevacizumab.
- You are healthy enough for a procedure to place a small reservoir (Ommaya) under your scalp for drug delivery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This Phase 1 study tests an “allogenic” stem cell product made from donated fat tissue to treat recurrent glioblastoma or certain recurrent astrocytoma. It gives the treatment around the time of a repeat brain surgery, and focuses on safety while also studying why it might help.
This trial tests a targeted radiation treatment (radioembolization) given through a artery into the brain for glioblastoma that has come back after standard therapy. It may help people whose tumor is in a single, accessible area.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
Hear when a new Recurrent Glioblastoma, IDH-Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.